RxDoctor Payments DataLook up a doctor →

Esther Tang

Nurse Practitioner · Winchester, VANPI 1841881620

Payments from drug & device makers

$15,948in general payments, 2019–2025

Across 698 payments — averaging $22.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$2K
  • UCB, Inc.$2K
  • AbbVie$1K
  • Jazz Pharmaceuticals Inc.$1K
  • SK Life Science, Inc.$942
  • Biogen$708
  • plus $8K from 47 others

What the payments were for

  • Travel & lodging$1,53110%
  • Food & beverage$14,04188%
  • Education$3762%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,948 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$69,484
Medicare patients
260
Services billed
5,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5025$906,218
BriviactBrivaracetam94$133,867
IngrezzaValbenazine Tosylate12$97,179
XcopriCenobamate73$90,085
EpidiolexCannabidiol (Cbd)18$39,409
LamictalLamotrigine29$37,611
KeppraLevetiracetam30$33,409
UbrelvyUbrogepant27$29,254
Lamotrigine OdtLamotrigine24$20,454
QuliptaAtogepant13$15,307
Nurtec OdtRimegepant Sulfate15$14,483
NayzilamMidazolam14$11,870
OnfiClobazam11$11,220
Aimovig AutoinjectorErenumab-Aooe14$10,543
Lacosamide94$9,918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt, Lyrica$575$928,31951 claims
UCB, Inc.Briviact, Nayzilam$1,714$145,737108 claims
Neurocrine Biosciences, Inc.Ingrezza$135$97,17912 claims
SK Life Science, Inc.Xcopri$942$90,08573 claims
AbbVieUbrelvy, Qulipta$1,308$44,56140 claims
Lundbeck LLCOnfi$523$11,22011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →